AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.
The device, which has clearance by the U.S. Food and Drug Administration (FDA), evaluated biparametric MR images and achieved an area under the curve (AUC) of 0.936. The study saw 13 board-certified abdominal radiologists reading the same prostate MR image sets with confirmed biological ground truth points. Compared with the device, they achieved an AUC of 0.742.
Bot Image further highlighted that the results show how ProstatID can aid in early detection, active surveillance, and treatment planning. It uses a linearly scaled risk score and the PI-RADS case scoring system. The device also provides clinical users with suspicious lesion targets to further focus on and grade in their clinical reports.
